SCHEMBL20596512

SCHEMBL20596512

CCOC(=O)Cc1cn2c(-c3ccc(OC)cc3Cl)cccc2n1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ F10 P00742 1/20 0.44
▸ KDM4E B2RXH2 4/20 0.43
▸ ALDH1A1 P00352 3/20 0.43
▸ SMN1; SMN2 Q16637 2/20 0.43
▸ KMT2A Q03164 2/20 0.43
▸ MAPK1 P28482 1/20 0.41
▸ MARS2 Q96GW9 4/20 0.41
▸ MAPT P10636 4/20 0.41
▸ CRHR1 P34998 2/20 0.41
▸ CDC7 O00311 1/20 0.41
▸ DBF4 Q9UBU7 1/20 0.41
▸ PDE4B Q07343 1/20 0.41
▸ PDE4D Q08499 1/20 0.41
▸ PPARG P37231 1/20 0.40
▸ GAA P10253 1/20 0.40
▸ JAK1 P23458 1/20 0.39
▸ THRB P10828 1/20 0.39
▸ FPR1 P21462 1/20 0.39
▸ RAB9A P51151 1/20 0.39
▸ HSD17B10 Q99714 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30145317 0.88 MARS2 (0.44) KDM4EALDH1A1SMN1; SMN2MAPK1MARS2
SCHEMBL30145335 0.87 MARS2 (0.43) F10SMN1; SMN2MAPK1MARS2MAPT
SCHEMBL20596598 0.84 F10 (0.43) F10KDM4EALDH1A1SMN1; SMN2KMT2A
SCHEMBL20596490 0.78 MARS2 (0.42) KDM4EALDH1A1SMN1; SMN2KMT2AMAPK1
SCHEMBL9001917 0.77 F10 (0.48) F10KDM4EALDH1A1SMN1; SMN2KMT2A
SCHEMBL20596557 0.77 MAPT (0.43) KDM4EALDH1A1SMN1; SMN2KMT2AMAPK1
SCHEMBL20595852 0.75 CYP11B1 (0.41) KDM4EALDH1A1CDC7DBF4PDE4B
SCHEMBL20595932 0.73 MARS2 (0.40) F10KDM4EALDH1A1SMN1; SMN2KMT2A
SCHEMBL20596633 0.73 GAA (0.47) F10KDM4EALDH1A1SMN1; SMN2KMT2A
SCHEMBL7982683 0.73 GAA (0.47) F10KDM4EALDH1A1KMT2AMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11584744-B2 Inhibitors of type 1 methionyl-tRNA synthetase and methods of using them UNIVERSITY OF WASHINGTON (US) 2023-02-21 — — US disclosed
US-11584744-B2 Inhibitors of type 1 methionyl-tRNA synthetase and methods of using them UNIVERSITY OF WASHINGTON (US) 2023-02-21 — — US disclosed
US-20210155617-A1 INHIBITORS OF TYPE l METHIONYL-TRNA SYNTHETASE AND METHODS OF USING THEM UNIVERSITY OF WASHINGTON 2021-05-27 — — US disclosed
US-20210155617-A1 INHIBITORS OF TYPE l METHIONYL-TRNA SYNTHETASE AND METHODS OF USING THEM UNIVERSITY OF WASHINGTON 2021-05-27 — — US disclosed
WO-2018237349-A1 INHIBITORS OF TYPED 1 METHIONYL-TRNA SYNTHETASE AND METHODS OF USING THEM UNIVERSITY OF WASHINGTON (US) 2018-12-27 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11584744-B2 Inhibitors of type 1 methionyl-tRNA synthetase and methods of using them AARS1, EMG1, GARS1 F10 4477/4885KDM4E 1618/4885ALDH1A1 1461/4885
US-20210155617-A1 INHIBITORS OF TYPE l METHIONYL-TRNA SYNTHETASE AND METHODS OF USING THEM AARS1, GARS1, MTR F10 4394/4885KDM4E 1423/4885ALDH1A1 2337/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback